Development of Immunogene therapy using IL-6 for Pancreatic Cancer

点击翻译按钮获取中文摘要

Production of interleukin-6 (IL-6) by human pancreatic carcinoma cells inversely correlates with potentials for blood-borne metastasis to the liver in nude mice. IL-6 cDNA was transfected to PCI-43, one of our cultured pancreatic carcinoma cell lines that does not produce IL-6 and generates numerous metastases to the liver. An IL-6 high-producer clone (PCI-43h) generated few metastases; IL-6 production thus has a direct effect on metastasis, whereas other transfectants (PCI-43l and PCI-43n), which are IL-6 low-, and IL-6 non-producers, respectively, did generate metastases. Tumor-reactive IgG, which mediated antibody-dependent cellular cytotoxicity (ADCC) in vitro, was detected in sera from recipient nude mice inoculated with PCI-43h but not in sera from mice given PCI-43l, PCI-43n or parent PCI-43. In addition, we tested the efficacy of N116Y in blocking the in vivo growth of pancreatic cancer cells using an adenoviral vector. Direct injection of the AdCEA-N116Y in which N116Y expression is driven by the CEA promoter, into the spleen in nude mice suppressed their growth of liver metastases significantly.